Interní Med. 2004; 6(8): 392-394

Krvácivé komplikace u nemocných léčených warfarinem

MUDr. Jiří Moláček1, Vladislav Třeška1, MUDr. Bohuslav Čertík Ph.D1, MUDr. František Šlauf2, DrSc
1 Chirurgická klinika FN Plzeň
2 Radiodiagnostická klinika FN Plzeň

Keywords: warfarin, bleeding complication, hemocoagulation factors.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Moláček J, Třeška V, Čertík B, Šlauf F, DrSc. Krvácivé komplikace u nemocných léčených warfarinem. Interní Med. 2004;6(8):392-394.

Jednou z nejzávažnějších komplikací při léčbě warfarinem je krvácení, které je nejčastěji do gastrointestinálního traktu (GIT), může se však objevit i v jiných oblastech, jako je retroperitoneum, stěna břišní, svaly atd. V moderní medicíně řeší krvácení do GIT nejčastěji nechirurgická pracoviště, pouze malé procento případů je nutno řešit chirurgicky. Základem terapie je vždy korekce hemokoagulačních parametrů, která je často plně dostačující k vyřešení krvácivé komplikace.Prevencí těchto příhod je pečlivá monitorace hemokoagulačních parametrů během léčby warfarinem.

Hemorrhagic Complications of Warfarin Therapy

The most common and serious complication of Warfarin therapy is bleeding, which largely occurs in gastrointestinal tract (GIT). However it may also occur in other regions such as retroperitoneum, abdominal wall, muscles, etc. Modern Medicine deals with bleeding in GIT mostly at non-surgery units, only low percentage of occurrences have to undergo surgery. The goal of the therapy is to administer the correction of hemocoagulation factors, which is very often fully sufficient to avoid hemorrhagic complications. A recommendation for the reversal of bleeding is the thorough monitoring of hemocoagulation factors during the Warfarin therapy performed most often by the physician.

Download citation

References

  1. Karetová D, Staněk F. Angiologie pro praxi, Maxdorf, Praha 2001.
  2. Phillips WS, Smith J, Greaves M, et al. An Evaluation and Improvement Program for Inpatient Anticoagulant Control (1997). Go to original source...
  3. Shetty HGM, Backhouse G. Effective reversal of warfarin - induced excessive anticoagulation with low dose vitamin K1.Thromb. and Haemostasis 67 (1) (1992). Go to original source...
  4. Třeška V. a kol. Propedeutika vybraných klinických oborů, Grada Publishing 2003; (267).
  5. Harvey RL, Lovell LL, Belanger N, Roth EJ. The effectiveness of anticoagulant and antiplatelet agents in preventing venous thromboembolism during stroke rehabilitation:A historica cohort study. Arch. Phys. Med. Rehabil. 2004; 85: 1070-1075. Go to original source... Go to PubMed...
  6. Farraj RS. Anticoagulation period in idiopathic venous thromboembolism. How long is enough? Saudi Med. J. 2004; 25: 848-851. Go to PubMed...
  7. Hylek EM. Complication of oral anticoagulant therapy: bleading and nonbleeding rates and risk factors, Semin. Vasc. Med., 2003; 3: 271-278. Go to original source... Go to PubMed...
  8. Gullov AL, Koefoed BG, Petersen P. Bleeding Complication to long term oral anticoagulant therapy, J. Thromb. Thrombolysis, 1994; 1: 17-25. Go to original source... Go to PubMed...
  9. Brigden ML. When bleeding complicates oralanticoagulant therapy. How to anticipate, investigate and treat. Postgrad. Med. 1995; 98: 153-154, 159-162. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.